Knight Therapeutics (GUD) Scheduled to Post Earnings on Thursday

Knight Therapeutics (TSE:GUD) will be issuing its quarterly earnings data before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of C$0.03 per share for the quarter.

Knight Therapeutics (TSE:GUD) last posted its earnings results on Thursday, May 9th. The company reported C($0.04) EPS for the quarter, missing analysts’ consensus estimates of C$0.02 by C($0.06). Knight Therapeutics had a negative return on equity of 2.21% and a negative net margin of 5.25%. The firm had revenue of C$86.60 million during the quarter, compared to analysts’ expectations of C$80.27 million.

Knight Therapeutics Trading Down 0.2 %

TSE GUD traded down C$0.01 during trading hours on Tuesday, hitting C$5.54. 56,193 shares of the company were exchanged, compared to its average volume of 65,019. The stock has a 50-day moving average price of C$5.69 and a 200 day moving average price of C$5.64. The company has a quick ratio of 1.79, a current ratio of 3.34 and a debt-to-equity ratio of 9.20. Knight Therapeutics has a 52 week low of C$4.35 and a 52 week high of C$6.22. The stock has a market cap of C$561.65 million, a PE ratio of -34.69, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.46.

Insiders Place Their Bets

In other Knight Therapeutics news, Director Jonathan Ross Goodman bought 5,000 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were purchased at an average price of C$5.80 per share, with a total value of C$29,000.00. In other news, Director Robert Nathaniel Lande sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of C$5.91, for a total transaction of C$88,600.50. Also, Director Jonathan Ross Goodman bought 5,000 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were acquired at an average cost of C$5.80 per share, for a total transaction of C$29,000.00. Insiders have sold 75,000 shares of company stock valued at $437,533 over the last ninety days. 46.36% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus boosted their price objective on Knight Therapeutics from C$5.40 to C$5.75 in a research note on Friday, May 10th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.